Collaborative Research Agreements (Details) (USD $)	12 Months Ended				12 Months Ended				1 Months Ended	12 Months Ended			12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Sep. 26, 2005	Dec. 31, 2012 Novartis [Member]	Jun. 04, 2010 Novartis [Member]	Dec. 01, 2004 Novartis [Member]	Dec. 31, 2012 Genta [Member]	Jun. 21, 2008 GLP-1 License Agreement [Member]	Dec. 31, 2012 GLP-1 License Agreement [Member]	Dec. 31, 2010 Insulins License Agreement [Member]	Dec. 31, 2012 Insulins License Agreement [Member]	Dec. 31, 2012 Salmon Calcitonin Agreements [Member]	Dec. 31, 2012 Oral PTH-1-34 Agreements [Member]
Indefinite-lived Intangible Assets [Line Items]
Sales and development excess amount										$ 87,000,000	$ 57,500,000			$ 25,000,000
Non-refundable license fee									10,000,000	10,000,000	5,000,000		2,500,000
Payment released to Emisphere by milestone										2,000,000
Initial upfront payment										10,000,000	5,000,000
Total deferred revenue	31,614,000	31,593,000								13,600,000		5,000,000
Milestone and upfront payments to agreements	0	0	7,000,000		12,400,000					2,000,000			2,000,000
Payment in support services										1,600,000
Convertible note issued				15,000,000			10,000,000
Amendment date of Novartis Agreement					Jun. 04, 2010
Reduction of future royalty and milestone payments					11,000,000	11,000,000
Outstanding principal balance and accrued interest					13,000,000	13,000,000
Excess amount in milestones payment					14,000,000			24,300,000
Expense of reimbursements	10,000	60,000	100,000
Collaborative Research Agreements (Textual) [Abstract]
Expenses in research and development	$ 0	$ 0	$ 0